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Introduction: Once thought to be radioresistant, emerging cellular and clinical evidence
now suggests melanoma can respond to large radiation doses per fraction. Materials
and Methods: We conducted a retrospective study of all patients treated with stereo-
tactic radiosurgery and stereotactic body radiotherapy at Georgetown University Hospital
from May 2002 through November 2008 and studied the classic extrapolated total dose
corrected for volume (ETDvol) model for predicting melanoma tumor response. Region-
speciﬁc tumor outcomes were categorized by RECIST criteria and local control curves
were estimated and analyzed when stratiﬁed by ETDvol thresholds by use of the Kaplan–
Meier method. Results: Follow-up information was available for 78 lesions (49 intracranial,
8 spinal, and 21 body) with mean follow-up period of 9.2 (range, 2–36) months. 1-year local
control rates for intracranial, spinal, and body tumors were 84, 100, and 72%, respectively.
Treatments in general were well-tolerated. Increased ETDvol (p < 0.001) among intracranial
sites resulted from larger (p < 0.001) doses per fraction combined with smaller (p < 0.001)
tumor diameters. Intracranial 6-, 12-, and 24-month local control rates when treated above
ETDvol threshold of 230 Gy were all 90 vs. 89, 80, and 53% below this threshold. Body 6-
and 12-month local control rates when treated above ETDvol threshold of 100 Gy were 100
and 80% vs. 74 and 59% below this threshold. Discussion: By tailoring to melanoma’s
unique radiobiology with large radiation doses per fraction, favorable local control was
safely achieved. The ETDvol model combines the important factor of dose per fraction in
melanoma treatment with a volume correction factor to predict tumor response. Although
limited sample size may have prevented reaching statistical signiﬁcance for local control
improvements using ETDvol thresholds, optimal thresholds may exist to improve future
tumor responses and further research is required.
Keywords: stereotactic radiosurgery, stereotactic body radiotherapy, malignant melanoma, linear quadratic
models, gray units
INTRODUCTION
Melanoma continues to be a signiﬁcant cause of morbidity and
mortality in the United States ranking as the ﬁfth most common
cancer in men and the seventh most common cancer in women
(Jemal et al., 2010). Its incidence has rapidly increased over the
past four decades, particularly among young adults (Reed et al.,
2012), and although melanoma was once classically thought to
be a radioresistant tumor based on cellular studies and clinical
experience that utilized low-dose radiation (Barranco et al., 1971;
Harwood andCummings, 1981), it is now believed thatmelanoma
cell lines have a wide range of sensitivity to radiation and can have
favorable responses to large radiation doses per fraction (Stevens
and McKay, 2006). The positive effects of large doses per fraction
have now been conﬁrmed by several clinical studies (Geara and
Kang, 1996; Khan et al., 2011). Due to melanoma’s high tendency
for locoregional recurrence and metastasis, radiation therapy is
increasingly utilized in settings including postresection adjuvant
therapy, palliative therapy, primary therapy, and additionally for
unresectable tumors (Schild, 2009). Recent ﬁndings have shown
promising results for melanoma tumors including for brain (Hara
et al., 2009) and nodal (Burmeister et al., 2012) metastases and
uveal melanoma (Modorati et al., 2009) among others. While still
limited, the current data suggests malignant melanoma appears
responsive to radiation when appropriate doses and fraction sizes
are used.
Because large fraction sizes are a concern for late radiation
complication risk, it is desirable to deliver radiation in a precise,
highly conformal fashion with a sharp dose-gradient outside the
tumor target, minimizing risk to proximal dose-limiting struc-
tures. These are characteristics of dose delivery using either
stereotactic radiosurgery (SRS) or stereotactic body radiation ther-
apy (SBRT) (Chang et al., 2003) making the assessment of these
techniques critical in the development of improved melanoma
radiation treatment. We studied outcomes in patients from our
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institution treated with SRS and SBRT.We further studied the util-
ity of the extrapolated total dose corrected for volume (ETDvol)
model as developed in the 1986 landmark Overgaard et al. (1986)
study as a predictor of melanoma tumor response using our
current ﬁndings.
MATERIALS AND METHODS
STUDY GROUP
This retrospective study was approved by the Institutional Review
Board (IRB) of Georgetown University. 146 melanoma lesions
treated with SRS and SBRT in 50 patients at Georgetown Uni-
versity from May 2002 through November 2008 were identiﬁed
with mean patient age 56.6 years (range, 31–92 years). 143 lesions
were metastatic and three were primary lesions located in the sella
turcica, maxillary sinus, and orbit. Tumors were categorized by
treatment site into intracranial, spinal, or body for all other sites.
89 tumors were intracranial, 19 were spinal, and 38 were located
elsewhere in the bodywhich included 11 lung andﬁve neck lesions.
Chemotherapy was previously delivered to 26 patients.
Intracranial lesions receiving prior treatment included four treated
with gamma knife SRS, seven treated with CyberKnife SRS, 23
treated with whole brain external beam radiation, and four sur-
gically resected. Spinal lesions receiving prior treatment included
six treated with external beam radiation and 14 surgically resected.
Body lesions receiving prior treatment included four treated with
external beam radiation and ﬁve surgically resected.
PROCEDURES
In our institution, SRS and SBRT are performed by the CyberKnife
(Chang et al., 2003) and treatment of primary melanoma and
melanoma metastases to intracranial, spinal, and other body sites
including cutaneous, orbital, abdominal, oral, adrenal, pericar-
dial, pulmonary, and sinus sites has been possible. Typically, SRS
in the brain entails accurate delivery of a single or limited num-
ber of high-dose fractions. Hypofractionated SBRT can combine
an ablative radiation dose with the use of modest fractionation to
improve sparing of adjacent normal tissues.
DATA ANALYSIS
Tumor outcomes were evaluated by serial CT, PET, and/or MRI
scans and categorized into local failure, stable disease, partial
response, or complete response by RECIST criteria (Eisenhauer
et al., 2009). Local control was also reported and was deﬁned as no
local tumor progression. The Radiation Therapy Oncology Group
(RTOG) toxicity scale was used. Last imaging dates and two-sided
statistical tests were used in all calculations.
We also assessed the utility of the ETDvol model as a guide for
SRS and SBRT dose selection and for predicting tumor outcome.
ETDvol was given by Overgaard et al. (1986)
ETDvol = Dd + 2.5
2.5
M−0.33
where D was total dose (Gy), d was dose per fraction (Gy), and
M was mean tumor diameter. We applied this equation to all 146
treated melanoma lesions. Odds ratios were calculated for region-
speciﬁc local control rates as a function of ETDvol above and below
set threshold values.
TheKaplan–Meiermethodwas used to estimate region-speciﬁc
local control curves as well as to compare region-speciﬁc local
control rates stratiﬁed by above or below ETDvol thresholds using
hazard ratios and log-rank tests. Time to local failure was censored
by loss to follow-up and death due to non-study outcomes.
RESULTS
TREATMENT PARAMETERS
Total doses ranged from 750 to 5400 cGy (mean 2410 cGy) in 1–5
fractions. Mean target volume was 57.8 cm3. Mean prescription
isodose line was 78.7% while the most commonly prescribed iso-
dose line was 85%. Mean target volume covered by the isodose
line was 96.5% with a mean ratio of max dose to prescribed dose
of 1.27.
Mean tumor diameter was 1.6 cm for intracranial sites, 5.2 cm
for spinal sites, and 5.4 cm for body sites. Mean dose per fraction
was 1710 cGy for intracranial sites, 887 cGy for spinal sites, and
966 cGy for body sites. Using two-tailed t-tests, intracranial tumor
dose per fraction was signiﬁcantly larger than spinal (p < 0.001)
and body tumors (p < 0.001), while intracranial tumor diameter
was signiﬁcantly smaller than spinal (p< 0.001) and body tumors
(p < 0.001).
TOXICITY
Using the RTOG toxicity scale, treatments in general were well-
tolerated with themost common acute side effects being headache
and nausea. These acute effects occurred exclusively in three
patients treated for intracranial sites. At last follow-ups, no late
toxicity was noted including myelitis and necrosis.
CLINICAL OUTCOMES
Follow-up information for tumor outcomes was available for
78 lesions across 26 patients including 49 intracranial, eight
spinal, and 21 body tumors which included ﬁve lung and four
neck tumors. Mean follow-up period was 9.2 months (range,
2–36 months). Among intracranial lesions, eight (16%) showed
complete response, 12 (24%) showed partial response, 19 (39%)
were stable and ten (20%) failed locally after treatment. Among
spinal lesions, four (50%) showed complete response and four
(50%) were stable. Among body lesions, six (29%) showed com-
plete response, one (5%) showed partial response, nine (43%)
were stable, and ﬁve (24%) failed locally. All ﬁve lung tumors and
two of three primary tumors were locally controlled with the sella
turcica lesion being the sole primary melanoma lesion that locally
failed. Figure 1 illustrates tumor outcomes for intracranial, spinal,
and body sites using RECIST criteria. To summarize, local con-
trol was achieved in 80% of intracranial tumors, 100% of spinal
tumors, and 76% of body tumors.
A Kaplan–Meier plot is displayed in Figure 2 of time from
treatment until local failure categorized by tumor region. No sta-
tistically signiﬁcant local control differences were found between
treatment sites. 6-, 12-, and 24-month local control rates for
intracranial tumors were 89, 84, and 61%, respectively. 6-,12-, and
18-month local control rates for spinal sites were 100%. 6- and
12-month local control rates for body tumors were 81 and 72%,
respectively. No statistically signiﬁcant local control differences
were found between treatment sites. Across all three sites log-rank
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FIGURE 1 | Region-specific tumor outcomes categorized by RECIST
criteria for intracranial (n = 49), spinal (n = 8), and body (n = 21) sites
following SRS and SBRT. Local control was achieved in 80, 100, and 76%
of intracranial, spinal, and body sites, respectively.
FIGURE 2 | Kaplan–Meier plot of probability of local tumor control by
site. No statistically signiﬁcant local control differences were found
between treatment sites (across all three sites log-rank p = 0.37,
intracranial vs. spinal log-rank p = 0.22, intracranial vs. body log-rank
p = 0.63, and spinal vs. body log-rank p = 0.16).
p = 0.37, intracranial vs. spinal log-rank p = 0.22, intracranial vs.
body log-rank p = 0.63, and spinal vs. body log-rank p = 0.16.
ETDvol THRESHOLD ANALYSIS
ETDvol was calculated for all 146 lesions that received treatment
(Figure 3). We noted a bimodal distribution of ETDvol with a cut-
off at 100 Gy. Across all tumor sites, mean ETDvol was 126.7 Gy
(range, 19.0–330.9 Gy). Mean ETDvol was 159.7 (range, 44.3–
283.4) for intracranial sites, 56.9 (range, 42.9–74.6) for spinal
sites, and 96.1 (range, 21.0–245.8) for body sites. Two-tailed t-
tests revealed mean intracranial ETDvol to be signiﬁcantly larger
than mean spinal (p < 0.001) and body (p < 0.001) ETDvol. 62
of 74 (84%) tumor sites that received ETDvol above the distribu-
tion cut-off of 100 Gy ETDvol were intracranial sites. Of the 72
FIGURE 3 | Histogram of calculated ETDvol for all 146 treated tumors.
Note the bimodal distribution with 62 of 74 (84%) tumors being intracranial
tumors beyond the 100 Gy ETDvol cut-off.
tumors that received less than 100 Gy, 27 (38%) were intracra-
nial, 19 (26%) were spinal, and 26 (36%) were elsewhere in
the body.
Tumor outcome as a function of ETDvol could only be analyzed
for intracranial and body tumors as there were no spinal failures.
Using all available tumor outcomes, an ETDvol threshold above
230 Gy for intracranial tumors yielded 90% (n = 10) local con-
trol with 40% (n = 4) complete response, 10% (n = 1) partial
response, 40% (n = 4) stable, and 10% local failure compared to
79% (n = 39) local control below this threshold with 10% (n = 4)
complete response, 31% (n = 12) partial response, 38% (n = 15)
stable, and 21% (n = 8) local failure. Body tumors which received
ETDvol above a threshold of 100 Gy had 83% (n = 6) local control
with 17% (n = 1) complete response, 0% partial response, 67%
(n = 4) stable, and 17% (n = 1) local failure compared to 73%
(n = 15) local control with 33% (n = 5) complete response, 7%
(n = 1) partial response, 33% (n = 5) stable, and 27% (n = 4)
local failure for tumors that received less than this threshold. Odds
ratios for local intracranial and body tumor control when treated
with doses above these thresholds were 2.70 and 1.82, respectively,
however, no statistical signiﬁcance was found (95% CI 0.30–
24.28 and 0.16–20.71, respectively) possibly reﬂecting limited
sample size.
Treatment groups above and below thresholds showed similar
demographics with no signiﬁcant differences in gender nor age
(intracranial, gender proportion Fischer’s exact test p = 0.32, age
two-tailed t-test p = 0.33, below threshold mean age 55.12 years
and SD 14.47 years vs. above threshold mean age 61.75 years and
SD 22.26 years; body, gender Fischer’s exact test p = 0.53, age two-
tailed t-test p = 0.65, age below threshold mean 52.53 years and
SD 17.47 years vs. above threshold mean age 56.33 years and SD
17.55 years).
Figure 4 displays a Kaplan–Meier plot of time from treatment
until local failure comparing intracranial and body tumors when
treated above and below respective ETDvol thresholds of 230 Gy
and 100 Gy. 6-, 12-, and 24-month local control rates for intracra-
nial sites treated above ETDvol threshold were all 90% while they
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FIGURE 4 | Kaplan–Meier plot of probability of local control for intracranial and body tumors stratified by above or below ETDvol thresholds of 230 Gy
and 100 Gy, respectively. Intracranial local control above vs. below threshold log-rank p = 0.36; body local control above vs. below threshold log-rank p = 0.34.
were 89, 80, and 53%, respectively when treated below thresh-
old ETDvol. 6- and 12-month local control rates for body sites
treated above ETDvol threshold were 100 and 80%while they were
74 and 59% for body sites treated below threshold ETDvol. How-
ever, statistical signiﬁcance was not achieved possibly reﬂecting
limited sample size (intracranial, hazard ratio [HR] 2.47, 95% CI
0.53–11.52, log-rank p = 0.36; body, HR 2.68, 95% CI 0.45–16.02,
log-rank p = 0.34).
DISCUSSION
We feel that it is feasible to deliver large doses of radiation in a
highly conformal hypofractionated manner using SRS and SRBT
to treat melanoma in metastatic and selected primary settings.
Our local control (Figures 1 and 2) and toxicity were encouraging
given the aggressive andmorbid nature of the disease and compare
favorably with other studies that have demonstrated a range of 68–
89% local control of melanoma with SRS and SBRT (Hatiboglu
et al., 2011; Bernard et al., 2012; Kelly et al., 2012).
Malignant melanoma’s historic classiﬁcation among radiore-
sistant tumors was, in part, related to intrinsic factors that were
seen in in-vitro cell survival curves (Fertil andMalaise, 1981,1987).
Radiation cell survival curves formelanomagenerally reveal a large
shoulder which indicates a relatively high capacity to repair radi-
ation damage (Bentzen et al., 1989). This implies that larger doses
per fraction may be a better therapeutic strategy. Rofstad et al.
(Rofstad, 1986; Rofstad et al., 1987) additionally found a role for
extrinsic factors and tumor heterogeneity when they discovered
radiation sensitivity of melanoma to vary within the same indi-
vidual patient according to the site of biopsy. One such extrinsic
factor for radiosensitivity is cellular oxygenation status at the
time of radiation, and hypoxia is a prominent characteristic of
melanomas. Re-oxygenation after fractionated radiation has been
well-documented in these tumors, however, and the presence of
this re-oxygenation may thus reduce the importance of hypoxia
on tumor outcomes (McNally, 1980; Rofstad, 1989; Olsen and
Rofstad, 1999).
The combination of radiobiologically important characteristics
of hypoxia and a large shouldered cell-survival curve supports
the use of hypofractionated radiation. The well-known risks of
large dose fraction radiation on normal tissue argue for highly
conformal dose delivery such as SRS and SBRT if this fraction
scheme is to be used. Our favorable tumor outcomes and low
toxicity utilizing these treatment modalities supported this line of
rationale.
In a landmark study by Overgaard et al. (1986), dose per frac-
tion was correlated with response in melanoma tumors while
total dose, nominal standard dose, and treatment time were not.
High doses per fraction yielded a signiﬁcantly improved response
(p < 0.001). The lack of inﬂuence of treatment time allowed a
linear quadratic model analysis yielding an α/β ratio of 2.5 Gy.
The authors were able to incorporate the α/β ratio and dose per
fraction into a crude formula to estimate an isoeffect for differ-
ent fractionation schedules. The authors improved this formula
by correcting for tumor volume resulting in the ETDvol formula.
The authors calculated tumor volume by incorporating tumor
diameter directly into the equation after empirical modiﬁcations
found a best ﬁt model. Although crude, this effectively removed
the inﬂuence of tumor size and produced a signiﬁcantly better
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prediction of response. The model combined the important
factor of dose per fraction in melanoma treatment with a vol-
ume correction factor to achieve an accurately ﬁtting dose–
response model.
We similarly applied this equation to our current SRS and SBRT
ﬁndings to evaluate its utility in determining optimal radiation
schedules and improving future tumor outcomes.We ﬁrst noted a
bimodal distribution of ETDvol with a cut-off at 100Gy (Figure 3).
Beyond the 100 Gy cut-off, tumors were found to be predom-
inantly comprised of intracranial sites. Of the three variables
which determine ETDvol, dose per fraction was signiﬁcantly larger
while tumor diameter was signiﬁcantly smaller among intracra-
nial sites. This had a combined effect to increase and right-shift
intracranial ETDvol resulting in the bimodal ﬁndings noted in
Figure 3.
Spinal tumor ETDvol thresholds could not be investigated due
to complete local control of spinal lesions. Although limited
sample size may have prevented reaching statistical signiﬁcance
for ETDvol threshold analysis of intracranial and body sites, it
appeared that ETDvol thresholds may exist to improve tumor
outcome. This would be in line with accumulating evidence
suggesting high doses per fraction are necessary for optimal
melanoma response. Treatment above a threshold ETDvol of
230 Gy for intracranial and 100 Gy for body lesions resulted in
higher local control rates when using all available tumor outcomes
and higher 6-,12-, and 24-month local control rates.
Limitations of this study include treatment parameter differ-
ences resulting from catering to individual patients and lesions
and relying on radiographic data from different imaging modali-
ties for endpoint assessment. Future studies should also investigate
symptom control as an endpoint for palliative cases and effects of
previous and concurrent therapy on tumor outcomes.
Although this study lacked a control group, low-dose ther-
apy has been classically found to be ineffective in controlling
melanoma tumors andmounting clinical studies (Geara andKang,
1996; Stevens and McKay, 2006; Khan et al., 2011) suggest high
dose per fraction to be the optimal method of treatment. Our
excellent local control rates using high dose per fraction therapy
appear to reafﬁrm this. In line with using high-dose therapy to
improve tumor outcomes, we hypothesized that ETDvol thresh-
olds may exist above which tumor control is improved. While
several studies report melanoma treatment doses, ETDvol, which
importantly corrects dosages for tumor volume and could aid in
optimizing dose schedules adaptable for futuremelanoma tumors,
to the best of our knowledge has not been reported outside the
original landmark Overgaard et al. (1986) study.
While there were no statistically signiﬁcant local control
improvements using ETDvol thresholds, this may have been due to
limited sample size as we did observe notable improvement above
a 230 Gy threshold for intracranial lesions and 100 Gy for body
lesions (overall: 90 vs. 75.7% in intracranial lesions and 83 vs. 73%
in body lesions; intracranial 6-, 12-, and 24-month: 90, 90, and
90% vs. 89, 80, and 53%; body 6- and 12-month: 100 and 80% vs.
74 and 59%). Further research is needed to elucidate any statis-
tically signiﬁcant improved tumor responses that may exist using
ETDvol thresholds.
There appears to be little evidence of resistance to SRS and
SBRT in the treatment of malignant melanoma. By tailoring to
the unique radiobiology of melanoma with delivery of high doses
per fraction, favorable rates of local control were safely achieved.
Although SRS and SBRT as currently delivered can be effective in
controlling these tumors, ETDvol thresholds may exist to optimize
radiation schedules and improve future melanoma tumor control.
Data is still lacking before speciﬁc thresholds can be recommended
and further research is required.
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